MIRM NASDAQ
Mirum Pharmaceuticals, Inc.
1W: -4.1%
1M: -9.3%
3M: +21.4%
YTD: +43.8%
1Y: +116.5%
3Y: +333.5%
5Y: +595.4%
$112.23
-1.97 (-1.73%)
Weekly Expected Move ±6.6%
$98
$106
$113
$120
$128
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$6.8B
52W Range50.25-130
Volume431,267
Avg Volume1,000,358
Beta0.48
Dividend—
Analyst Ratings
Company Info
CEOChristopher Peetz
Employees418
SectorHealthcare
IndustryBiotechnology
IPO Date2019-07-18
Websitemirumpharma.com
950 Tower Lane
Foster City, CA 94404
US
Foster City, CA 94404
US
650 667 4085
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Latest News
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Peetz Christopher | S-Sale | 12,134 | $121.65 | 2026-07-06 |
| Peetz Christopher | S-Sale | 4,181 | $122.34 | 2026-07-06 |
| Peetz Christopher | S-Sale | 1,975 | $123.74 | 2026-07-06 |
| Peetz Christopher | S-Sale | 1,710 | $124.79 | 2026-07-06 |
| BJERKHOLT ERIC | S-Sale | 3,124 | $121.67 | 2026-07-06 |